Rankings / Metabolic Health

Tesofensine

Metabolic Health · Triple monoamine reuptake inhibitor

Tier D+

High-risk evidence profile

Reviewed by Read Off Label · Last reviewed · How we grade

investigationaldopamineserotonin
High-risk evidence profile
3.7 / 10
Tier D+
Ev 3 Bn 6.5 Sf 3.5

Bottom line

Read Off Label grades Tesofensine as D+ (3.7/10) based on weak evidence, med-high benefit magnitude, and a med-high-risk safety profile.

Its high-risk evidence profile reflects a Safety score of 3.5/10; reported benefits and harms can differ by indication, dose, route, duration, and population.

Saniona now developing for hypothalamic obesity (rare disease orphan indication).

Studied, labeled, or reported-use context: 0. — Investigational in multiple jurisdictions; not approved; not individualized guidance.

Frontier potential — editorial judgment, not evidence

This is a separate axis from the grade above. It asks a different question: if this worked in humans, how much would it matter? It is our judgment, it is not part of the composite score, and it cannot raise a grade. A high number here is a statement about the idea, not about whether it works or whether anyone should take it.

5/10
Real mechanism, modest ceiling Phase 3

What the ceiling rests on

A triple monoamine reuptake inhibitor that produced roughly double the weight loss of the anti-obesity drugs available at the time of its Phase 2, which was a striking result and is why it remains discussed.

Why it may not get there

Development stalled over cardiovascular and psychiatric tolerability — heart rate and blood pressure increases, plus mood effects consistent with its mechanism. The triple-monoamine class has a poor regulatory history for exactly these reasons. It has since been overtaken by incretins that achieve comparable or greater loss with a better safety profile, which lowers the ceiling on relevance as much as on efficacy.

What would change this A regulatory approval in any major market.

What the evidence says

Saniona now developing for hypothalamic obesity (rare disease orphan indication). Substantial weight loss in obesity trials. Cognitive trials disappointed. Research chem availability exists; caution with CV effects.

Mechanism

Inhibits DAT, NET, SERT; originally developed by NeuroSearch for Alzheimer's/Parkinson's (failed primary endpoints); repurposed for obesity with striking weight loss effects

Studied, labeled, or reported dose & route

0.25-1 mg/day PO in obesity trials

This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.

Citations

A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.

Common questions

What does the evidence show about Tesofensine's effects?
Read Off Label rates the evidence for Tesofensine as Weak and the benefit magnitude as med-high, producing an overall grade of D+ (3.7/10). Saniona now developing for hypothalamic obesity (rare disease orphan indication).
What safety findings are reported for Tesofensine?
Tesofensine has a med-high risk profile in the database. Med-High (tachycardia, BP elevation, insomnia, mood changes) Legal status: Investigational in multiple jurisdictions; not approved.
What does the low Safety score for Tesofensine represent?
The Safety score is 3.5/10. It records the substantial harms described for one or more use contexts; the Benefit score, indication, dose, route, duration, population, and legal status remain separate parts of the evidence profile.
What doses or routes are reported for Tesofensine?
0.25-1 mg/day PO in obesity trials This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
How does Tesofensine work?
Inhibits DAT, NET, SERT; originally developed by NeuroSearch for Alzheimer's/Parkinson's (failed primary endpoints); repurposed for obesity with striking weight loss effects

This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.